Posts Tagged ‘access to care’

NHS Says: “We Cannot Treat Our Way Out of Obesity”

July 9, 2024 — If one is looking for a hint about the cluelessness of the NHS in dealing seriously with obesity, they can find a double dose in reporting on priorities of England’s 42 integrated care boards. First there is the analysis. More than 85% of those boards think obesity is not a priority for health. Two of […]

The DiRECT Obsession with Behavior Change for Diabetes

July 7, 2024 — Letting go is hard. But there is a bright line between persistence and stubbornness. Persistence is absolutely necessary to advance a cause. But persistence gives way to stubbornness when facts line up to define serious limitations and people press on with a futile effort. Such is the case with the DiRECT obsession for “curing” type […]

A System of High Prices, Stigma, and Inequity in Obesity

July 3, 2024 — Nope, says Dr. Alissa Chen. Medicare shouldn’t start covering obesity medicines. Her dad, 72, has obesity that began when he was in grad school and has persisted throughout his life. Now he has the cardiovascular disease that often results from untreated obesity. But no, she doesn’t want him to receive treatment with advanced medicines proven […]

Momentum! TROA Passed in House Ways and Means

June 28, 2024 — With a bipartisan a vote of 36-4 yesterday, the House Ways and Means Committee passed an amended version of TROA – the Treat and Reduce Obesity Act. Honestly, after a decade of toiling away to educate legislators about the need for this, we need a pinch to assure ourselves it’s real. This is great  news […]

Getting Serious About Obesity Care in Medicare

June 27, 2024 — Today for the first time ever, the U.S. House Ways and Means Committee will be marking up the Treat and Reduce Obesity Act on Capitol Hill. This is a big deal simply because it means that finally, after a decade of advocacy efforts, Congress is getting serious about obesity care in Medicare. Technically, what the […]

Generic Liraglutide Is Here – Will It Make Any Difference?

June 26, 2024 — One of the four dimensions that sum to a terrible problem of inadequate scale in obesity care is cost. Right now, the list prices for obesity medicines like semaglutide and tirzepatide in the U.S. put them out of reach for all but the wealthy and the well-insured. So will it help that a generic GLP-1 agonist – […]

ADA2024: How Big Is the Problem with Scale for Obesity Care?

June 24, 2024 — One thing is plain to us in the huge showing of interest in obesity at the American Diabetes Association Scientific Sessions (ADA2024). The scale of opportunity is large because the unmet medical need is great. And yet we face a tremendous problem of scale for coping with the need for obesity care. We have problems […]

The Tide of Obesity Medicines Rolling into Health Plans

June 20, 2024 — It’s quite weird, actually, watching the contortions of health plans as they twist to resist the rising tide of obesity medicines. Because despite the twisting and contortions, obesity medicines are as difficult to resist as a rising tide. Those who pretend it is not happening find themselves under water. A new survey from the International […]

Can Novo Nordisk Dodge a Senate Subpoena on Pricing?

June 12, 2024 — Senator Bernie Sanders doesn’t want to let this go. Novo Nordisk isn’t eager to cut its thousand-dollar list price for Ozempic. Nor is it eager to face a grilling about this in the Senate. So yesterday, Sanders announced that the Senate Health, Education, Labor, and Pensions committee will vote next Tuesday on a subpoena for […]

Marginalizing People with the Greatest Need for Obesity Care

June 3, 2024 — The STOP Obesity Alliance released new data Friday from an exhaustive analysis of access to obesity medicines in Medicaid programs across the United States. It’s not a pretty picture. It gives us more data to show how we are marginalizing people with the greatest need for obesity care. No state fully covered all forms of […]